z-logo
open-access-imgOpen Access
Pifithrin‐α Enhances the Survival of Transplanted Neural Stem Cells in Stroke Rats by Inhibiting p53 Nuclear Translocation
Author(s) -
Lei XuHui,
Zhao Dan,
Li YongLi,
Li XianFeng,
Sun Xu,
Du WenZhong,
Sun Ying,
Hao ZhongFei,
Xin ShiYue,
Liu Cong,
Zhang ZhiRen,
Jiang ChuanLu
Publication year - 2013
Publication title -
cns neuroscience and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 69
eISSN - 1755-5949
pISSN - 1755-5930
DOI - 10.1111/cns.12045
Subject(s) - neural stem cell , tunel assay , apoptosis , transplantation , chromosomal translocation , viability assay , cell , biology , chemistry , stem cell , cancer research , microbiology and biotechnology , medicine , biochemistry , gene
Summary Aims To examine a novel strategy to enhance the survival of grafted neural stem cells ( NSC s) in stroke model. Methods Using a cell counting kit‐8 ( CCK ‐8) and TUNEL assay to test the protective effects of p53 inhibitor, pifithrin‐α ( PFT ‐α), on oxygen glucose deprivation ( OGD ) in NSC s. We compared the effects of vehicle +  NSC s and FFT ‐α +  NSC s on the efficacy of transplantation in stroke rat model using behavioral analysis, immunohistochemistry, etc. Results Pifithrin‐α increased viability and decreased apoptosis in NSC s after OGD in vitro . By in vivo studies, we showed that the best recovery of neurological function in the stroke rats and the maximum survival of grafted NSC s were found in the PFT ‐α +  NSC s group. Twelve hours after cell transplantation, p53 was localized to the nuclei of grafted NSC s in the vehicle +  NSC s group but was primarily localized to the cytoplasm in the PFT ‐α +  NSC s group. The p53‐upregulated modulator of apoptosis ( PUMA ) was highly expressed among the grafted cells in the vehicle +  NSC s group compared with that in the PFT ‐α +  NSC s group. Conclusion Our results indicate that PFT ‐α enhances the survival of grafted NSC s through the inhibition of p53 translocation into the nucleus.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here